Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin | NCT01913964 | Trialant
CompletedInterventionalPhase 4Updated Aug 1, 2013
Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin
ClinicalTrials.gov ID
NCT01913964
Lead Sponsor
University of CataniaOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Last Update Posted
Aug 1, 2013Estimated
Start Date
Oct 1997
Primary Completion Date
Oct 1997Actual
Completion Date
Oct 1997Actual
Brief Summary
To assess the effects of Acetyl-L-Carnitine administration on work productivity, daily activity, and fatigue in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b and Ribavirin.
Work Productivity and Activity Impairment in Workers With Chronic C Hepatitis
Fatigue in Workers With Chronic C Hepatitis
Fatigue
Acetylcarnitine
Placebo
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
Yes
Eligibility Criteria
Inclusion Criteria:
workers who were 18 years of age or older
Workers who were infected by HCV and had a quantifiable serum HCV RNA level (as determined by polimerase chain reaction, COBAS AmpliPrep/COBAS TaqMan - ROCHE)
Cirrhotic workers with a Child-Pugh score less than 7